Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1982 Oct;46(4):687–693. doi: 10.1038/bjc.1982.256

Cellular immune function study in an ovarian cancer-prone kindred.

G S Schuelke, H T Lynch, J F Lynch, E A Chaperon, J A Recabaren, B Grabner, W A Albano
PMCID: PMC2011189  PMID: 7138773

Full text

PDF
687

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Badger A. M., Oh S. K., Moolten F. R. Differential effects of an immunosuppressive fraction from ascites fluid of patients with ovarian cancer on spontaneous and antibody-dependent cytotoxicity. Cancer Res. 1981 Mar;41(3):1133–1139. [PubMed] [Google Scholar]
  2. Byers V. S., Levin A. S., Hackett A. J., Fudenberg H. H. Tumor-specific cell-mediated immunity in household contacts of cancer patients.. J Clin Invest. 1975 Mar;55(3):500–513. doi: 10.1172/JCI107956. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Daunter B., Khoo S. K., Mackay E. V. Lymphocyte response to plant mitogens. I. The distribution of lymphocyte response of various doses of phytohemagglutinin-M in pregnant women and women with carcinoma of the cervix or ovary. Gynecol Oncol. 1979 Jun;7(3):309–313. doi: 10.1016/0090-8258(79)90108-2. [DOI] [PubMed] [Google Scholar]
  4. Dean J. H., Greene M. H., Reimer R. R., LeSane F. V., McKeen E. A., Mulvihill J. J., Blattner W. A., Herberman R. B., Fraumeni J. F., Jr Immunologic abnormalities in melanoma-prone families. J Natl Cancer Inst. 1979 Nov;63(5):1139–1145. [PubMed] [Google Scholar]
  5. Gerber M. A., Koffler D., Cohen C. J. Circulating antibodies in patients with ovarian carcinoma. Gynecol Oncol. 1977 Sep;5(3):228–232. doi: 10.1016/0090-8258(77)90030-0. [DOI] [PubMed] [Google Scholar]
  6. Graham-Pole J., Ogg L. J., Ross C. E., Cochran A. J. Sensitisation of neuroblastoma patients and related and unrelated contacts to neuroblastoma extracts. Lancet. 1976 Jun 26;1(7974):1376–1379. doi: 10.1016/s0140-6736(76)93027-0. [DOI] [PubMed] [Google Scholar]
  7. Guirgis H. A., Lynch H. T., Harris R. E., Vandevoorde J. P. Genetic and communicable effects on carcinoembryonic antigen expressivity in the cancer family syndrome. Cancer Res. 1978 Aug;38(8):2523–2528. [PubMed] [Google Scholar]
  8. Hersey P., Edwards A., Honeyman M., McCarthy W. H. Low natural-killer-cell activity in familial melanoma patients and their relatives. Br J Cancer. 1979 Jul;40(1):113–122. doi: 10.1038/bjc.1979.147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hess A. D., Gall S. A., Dawson J. R. Inhibition of in vitro lymphocyte function by cystic and ascitic fluids from ovarian cancer patients. Cancer Res. 1979 Jul;39(7 Pt 1):2381–2389. [PubMed] [Google Scholar]
  10. Hughes N. R. Serum concentrations of G, A, and M immunoglobulins in patients with carcinoma, melanoma, and sarcoma. J Natl Cancer Inst. 1971 May;46(5):1015–1028. [PubMed] [Google Scholar]
  11. Humphrey L., Panoussopoulos D., Volenec F. J., Masterson B. J., Jewell W. Role of tumor immunity in ovarian cancer. South Med J. 1977 Oct;70(10):1186–1187. doi: 10.1097/00007611-197710000-00009. [DOI] [PubMed] [Google Scholar]
  12. Lynch H. T., Albano W., Black L., Lynch J. F., Recabaren J., Pierson R. Familial excess of cancer of the ovary and other anatomic sites. JAMA. 1981 Jan 16;245(3):261–264. [PubMed] [Google Scholar]
  13. Mandell G. L., Fisher R. I., Bostick F., Young R. C. Ovarian cancer: a solid tumor with evidence of normal cellular immune function but abnormal B cell function. Am J Med. 1979 Apr;66(4):621–624. doi: 10.1016/0002-9343(79)91172-0. [DOI] [PubMed] [Google Scholar]
  14. Mantovani A., Allavena P., Sessa C., Bolis G., Mangioni C. Natural killer activity of lymphoid cells isolated from human ascitic ovarian tumors. Int J Cancer. 1980 May 15;25(5):573–582. doi: 10.1002/ijc.2910250505. [DOI] [PubMed] [Google Scholar]
  15. Mantovani A., Polentarutti N., Peri G., Shavit Z. B., Vecchi A., Bolis G., Mangioni C. Cytotoxicity on tumor cells of peripheral blood monocytes and tumor-associated macrophages in patients with ascites ovarian tumors. J Natl Cancer Inst. 1980 Jun;64(6):1307–1315. doi: 10.1093/jnci/64.6.1307. [DOI] [PubMed] [Google Scholar]
  16. Mikulski S. M., Billing R., Terasaki P. I. Inhibition of effector cell function in human antibody-dependent cellular cytotoxicity by sera from cancer patients. J Natl Cancer Inst. 1977 May;58(5):1485–1487. doi: 10.1093/jnci/58.5.1485. [DOI] [PubMed] [Google Scholar]
  17. Nair P. N., Fernandes G., Onoe K., Day N. K., Good R. A. Inhibition of effector cell functions in natural killer cell activity (NK) and antibody-dependent cellular cytotoxicity (ADCC) in mice by normal and cancer sera. Int J Cancer. 1980 May 15;25(5):667–677. doi: 10.1002/ijc.2910250518. [DOI] [PubMed] [Google Scholar]
  18. Pattillo R. A., Ruckert A. C., Story M. T., Mattingly R. F. Immunodiagnosis in ovarian cancer: blocking factor activity. Am J Obstet Gynecol. 1979 Apr 1;133(7):791–802. doi: 10.1016/0002-9378(79)90116-9. [DOI] [PubMed] [Google Scholar]
  19. Pattillo R. A., Story M. T., Ruckert A. C. Expression of cell-mediated immunity and blocking factor using a new line of ovarian cancer cells in vitro. Cancer Res. 1979 Apr;39(4):1185–1192. [PubMed] [Google Scholar]
  20. Poulton T. A., Crowther M. E., Hay F. C., Nineham L. J. Immune complexes in ovarian cancer. Lancet. 1978 Jul 8;2(8080):72–73. doi: 10.1016/s0140-6736(78)91383-1. [DOI] [PubMed] [Google Scholar]
  21. Ren E. C., Chan S. H. Inhibition of lymphocyte proliferation by sera from patients with hepatocellular carcinoma: lack of correlation with serum alpha-fetoprotein levels. J Natl Cancer Inst. 1981 Apr;66(4):625–630. [PubMed] [Google Scholar]
  22. Schuelke G. S., Lynch H. T., Lynch J. F., Fain P. R., Chaperon E. A. Low serum IgA in a familial ovarian cancer aggregate. Cancer Genet Cytogenet. 1982 Jul;6(3):231–236. doi: 10.1016/0165-4608(82)90060-7. [DOI] [PubMed] [Google Scholar]
  23. Ueda K., Toyokawa M., Nakamori H., Sako H., Umesaki N., Nakade J., Lee T., Sugawa T. Immunosuppressive effect of serum in patients with ovarian carcinoma. Obstet Gynecol. 1978 Feb;51(2):225–228. [PubMed] [Google Scholar]
  24. Ueda K., Toyokawa M., Nakamori H., Sako H., Umesaki N., Nakade J., Lee T., Sugawa T. The prognostic value of serum immunosuppressive effect in patients with ovarian cancer. Obstet Gynecol. 1979 Apr;53(4):480–483. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES